Brilinta, a new antiplatelet drug

August 2011

You'll hear lots of buzz about Brilinta, a new antiplatelet drug.

Brilinta (ticagrelor) will compete with Plavix (clopidogrel) and Effient (prasugrel)...for acute coronary syndrome or after a stent.

Plavix will still lead the pack...for a while. It was the first one approved and is used the most. But it's not perfect.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Antiplatelets Brilinta, a new antiplatelet drug
Hepatitis C two new protease inhibitors for hepatitis C, Incivek (telaprevir) and Victrelis (boceprevir)
Anticoagulants new ORAL anticoagulant called Xarelto (zuh-REL-toe)
Statins if statins increase the risk of diabetes
Men's Health Staxyn (STAX-in), a new orally disintegrating tablet version of vardenafil (Levitra)
Men's Health new warnings about the risk of prostate cancer with finasteride (Proscar, etc) or dutasteride (Avodart, etc)
Respiratory & Allergy which long-acting bronchodilator to use first-line for COPD
Pneumonia You wouldn't think IV dexamethasone would be a good idea for a patient hospitalized with community-acquired pneumonia (CAP)
Vitamins & Minerals Is it ever necessary to give vitamin B12 by injection
Psychiatry New VA guidelines for post-traumatic stress disorder
Sunscreens New rules for sunscreens
Smoking Cessation new warnings about Chantix and an increased risk of cardiac events in patients with heart disease